UPADACITINIB

Information current as at: 1 June 2026

PBAC meeting date: November 2020
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Rinvoq®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:
AbbVie Pty Ltd
Condition/indication:
(therapeutic use)
  • Severe rheumatoid arthritis
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC Submission type:
Change to listing (Minor submission)
Comment:
The PBAC provided additional advice to the Minister (under section 101(3) of the National Health Act 1953 (“the Act”)), in relation to its recommendation made between 6 – 8 November 2019 for the drug upadacitinib.
Other PBAC consideration:
--

Progress Details

Submission received for:
November 2020 PBAC meeting
Opportunity for consumer comment:
Open 26/08/2020 and close 07/10/2020 (see PBS Website)
PBAC meeting:
Held on 04/11/2020
PBAC outcome published:
Not Applicable (see PBAC Outcomes)
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Case ID
a269
Page last updated
31 March 2026
Return to the Medicine Status Listing
v.9.19